Myasthenia gravis chest x ray
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Keanu Ngo[2]
|
Myasthenia gravis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Myasthenia gravis chest x ray On the Web |
|
American Roentgen Ray Society Images of Myasthenia gravis chest x ray |
|
Risk calculators and risk factors for Myasthenia gravis chest x ray |
Overview
Chest X-ray (CXR) has low sensitivity and specificity for detecting thymic pathology associated with myasthenia gravis (MG). While historic literature supported its use to screen for thymic hyperplasia or thymoma, CXR frequently fails to visualize subtle anterior mediastinal lesions and cannot reliably distinguish non-neoplastic thymic tissue from malignant thymomas. Cross-sectional imaging—chest CT or MRI—is the accepted standard for thymoma screening and evaluation of anterior mediastinal masses in MG; around 90% of tumors are correctly identified on initial CT or MRI with a specificity of approximately 95%. For thymoma detection, non-contrast CT is not less sensitive than contrast-enhanced CT and is a reasonable initial method; contrast-enhanced CT or MRI is reserved for characterizing a suspected tumor and assessing invasion.[1][2]
Chest X-Ray
Indications
- Not a substitute for thymic screening: CXR is inadequate to screen for or exclude thymoma; approximately 40% of thymomas are missed on plain film, and a normal CXR never excludes a tumor. Cross-sectional imaging is required.[3][4]
- Evaluation of Acute Respiratory Symptoms: Indicated in patients with MG presenting with acute dyspnea, suspected aspiration pneumonia, atelectasis, or respiratory failure (e.g., suspected myasthenic crisis).
- Preoperative Baseline: Performed as standard baseline cardiothoracic evaluation prior to surgical interventions, including thymectomy.
Clinical Context and Disease Prevalence
Thymoma occurs in roughly 15% of MG patients and thymic hyperplasia in a majority; screening is nonetheless low-yield in MuSK-antibody-positive and AChR-antibody-negative disease. Striational (anti-titin/RyR) antibodies do not outperform CT for predicting thymoma, and a negative result does not exclude it—about 45% of MG-thymoma patients are striational-negative.[1][5] Neither CT nor MRI reliably distinguishes thymic hyperplasia from a normal gland, so imaging short of a discrete mass should be interpreted cautiously.[2]
Characteristic Findings
When thymic pathology is sufficiently large to be visible on CXR, characteristic findings include:
- Anterior Mediastinal Mass: Soft-tissue mass or retrosternal fullness best identified on the lateral view within the anterior mediastinal space.
- Widened Mediastinum: Widening of the superior or middle mediastinal contours on the posteroanterior (PA) view.
- Asymmetric Cardiothymic Silhouette: Lobulated or focal convexities altering the normal cardiovascular contours.
- Calcification: Rim or punctate calcifications within the anterior mediastinum, which may suggest a calcified thymoma.
Diagnostic Accuracy and Limitations
In a surgical series of 154 MG patients, subtle plain-film findings correctly predicted thymoma in only 15 of 26 cases (58%), whereas CT achieved a sensitivity of 85%, specificity of 98.7%, and accuracy of 95.8%.[3] The likelihood of thymoma rises with age (≈3% at ≤20 years, ≈12% at 21–45 years, ≈35% at >45 years); small tumors are readily hidden within the dense thymus of adolescents and by residual parenchymal islands in young adults.[3]
| Parameter | Diagnostic Characteristic / Clinical Impact |
|---|---|
| Sensitivity | Low (≈58% in surgical cohorts); routinely misses small thymomas, focal thymic hyperplasia, and microscopic disease. |
| Specificity | Low; cannot reliably differentiate normal tissue, thymic hyperplasia, benign cysts, or malignant thymomas. |
| Superimposition | Cardiac silhouette, sternum, and vascular structures overlap the anterior mediastinum on PA views, obscuring pathology. |
| Clinical Utility | Inadequate for standalone preoperative planning or definitive exclusion of thymic malignancy. |
Comparison with Cross-Sectional Modalities
Chest CT and MRI are significantly superior to plain radiographs for thymic evaluation.[6] Detailed performance metrics, protocols, and differential characteristics of these modalities are covered in the dedicated CT and MRI microchapters.
References
- ↑ 1.0 1.1 Punga AR, Maddison P, Heckmann JM, Guptill JT, Evoli A (2022). "Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders". Lancet Neurol. 21 (2): 176–188. doi:10.1016/S1474-4422(21)00297-0. PMID 34958509 Check
|pmid=value (help). - ↑ 2.0 2.1 Klimiec E, Quirke M, Leite MI, Hilton-Jones D (2018). "Thymus imaging in myasthenia gravis: The relevance in clinical practice". Muscle Nerve. 58 (4): 707–713. doi:10.1002/mus.26075. PMID 29890786.
- ↑ 3.0 3.1 3.2 Ellis K, Austin JH, Jaretzki A (November 1988). "Radiologic detection of thymoma in patients with myasthenia gravis". AJR Am J Roentgenol. 151 (5): 873–81. doi:10.2214/ajr.151.5.873. PMID 3263017.
- ↑ Batra P, Herrmann C, Mulder D (March 1987). "Mediastinal imaging in myasthenia gravis: correlation of chest radiography, CT, MR, and surgical findings". AJR Am J Roentgenol. 148 (3): 515–9. doi:10.2214/ajr.148.3.515. PMID 3492878.
- ↑ Shelly S, Mills JR, Dubey D, et al. (2021). "Clinical utility of striational antibodies in paraneoplastic and myasthenia gravis paraneoplastic panels". Neurology. 96 (24): e2966–e2976. doi:10.1212/WNL.0000000000012050. PMID 33980754 Check
|pmid=value (help). - ↑ Brown LR, Muhm JR, Sheedy PF, Unni KK, Bernatz PE, Hermann RC (January 1983). "The value of computed tomography in myasthenia gravis". AJR Am J Roentgenol. 140 (1): 31–5. doi:10.2214/ajr.140.1.31. PMID 6600322.